DR info

Clinical trials : 39 / Drugs : 35 - (DrugBank : 12) / Drug target genes : 13 - Drug target pathways : 45

Peroxisomal disease (except Adrenoleukodystrophy) and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability

ID	Diseases (Sorted by drug repositionability)
234	Peroxisomal disease (except Adrenoleukodystrophy)
20	Adrenoleukodystrophy
96	Crohn disease
46	Malignant rheumatoid arthritis
60	Aplastic anemia
19	Lysosomal storage disease
49	Systemic lupus erythematosus
326	Osteopetrosis
283	Acquired pure red cell aplasia
95	Autoimmune hepatitis
62	Paroxysmal nocturnal hemoglobinuria
284	Diamond-Blackfan anemia
61	Autoimmune hemolytic anemia
40	Takayasu arteritis
285	Fanconi anemia
164	Oculocutaneous albinism
93	Primary biliary cholangitis
11	Myasthenia gravis
36	Epidermolysis bullosa
28	Systemic amyloidosis
65	Primary immunodeficiency
85	Idiopathic interstitial pneumonia
51	Scleroderma
224	Purpura nephritis
13	Multiple sclerosis/Neuromyelitis optica
286	Hereditary sideroblastic anemia
45	Eosinophilic granulomatosis with Polyangiitis
302	Leber hereditary optic neuropathy
42	Polyarteritis nodosa
162	Pemphigoid
228	Bronchiolitis obliterans
66	IgA nephropathy
151	Rasmussen encephalitis
53	Sjogren syndrome
222	Primary nephrotic syndrome
226	Interstitial cystitis with Hunners ulcer
2	Amyotrophic lateral sclerosis
39	Toxic epidermal necrolysis
55	Relapsing polychondritis
299	Cystic fibrosis
97	Ulcerative colitis
274	Osteogenesis Imperfecta
6	Parkinson disease
38	Stevens-Johnson syndrome
269	Pyogenic arthritis
64	Thrombotic thrombocytopenic purpura
160	Congenital ichthyosis
227	Osler disease
41	Giant cell arteritis
158	Tuberous sclerosis
56	Behcet disease
26	HTLV-1-associated myelopathy
63	Idiopathic thrombocytopenic purpura
50	Dermatomyositis
58	Hypertrophic cardiomyopathy
90	Retinitis pigmentosa
107	Juvenile idiopathic arthritis
113	Muscular dystrophy
94	Primary sclerosing cholangitis